CompletedPhase 4NCT00707772
Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection
Studying Congenital factor XI deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Baqiyatallah Medical Sciences University
- Principal Investigator
- Professor Seyed-Moayed Alavian, ProfessorBaqiyatallah Research Center for Gastroenterology and Liver Diseases
- Intervention
- PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)(drug)
- Enrollment
- 400 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2007 – 2009
Study locations (1)
- Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Tehran, Tehran Province, Iran
Collaborators
Baqiyatallah Research Center for Gastroenterology and Liver Diseases · Tehran Hepatitis Center · Guilan University of Medical Sciences · Tabriz Research Center for Gastroenterology and Liver Diseases · Shahid Beheshti University of Medical Sciences · Iran University of Medical Sciences
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00707772 on ClinicalTrials.gov